The University of Alabama at Birmingham Callahan Eye Hospital has been named one of the newest sites for Spark Therapeutics’ Luxturna, the first gene therapy treatment approved by the Food and Drug Administration for a genetic disease. Dr. Jason Crosson (UAB) It is a prescription gene therapy for patients with inherited retinal disease due to mutations in both […]